Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Netherlands
In shortQiagen N.v. is profitable, generates cash and carries moderate debt, with revenue growing (+5.7% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 22.4% | 91/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 20.9% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 11.5% | 57/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 7.5% | 50/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.91× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.37× | 91/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 0.90× | 88/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 12.36× | 100/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 5.14 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 29.4% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.41× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 11.2% | 70/100 |
| Operating margin volatility | 8.6% | 31/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -0.8% | 12/100 |
|---|---|---|
| EPS growth, 3-year average | -7.2% | 0/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 2,252 | 2,143 | 1,965 | 1,978 | 2,090 |
| Cost of revenue | 805 | 767 | 737 | 1,016 | 797 |
| Gross profit | 1,446 | 1,376 | 1,228 | 962 | 1,293 |
| Research & development | 181 | 181 | 192 | 183 | 177 |
| Operating income | 636 | 533 | 413 | 117 | 468 |
| Interest expense | 56 | 60 | 56 | 47 | 38 |
| Pre-tax income | 651 | 667 | 574 | 191 | 507 |
| Income tax | 114 | 91 | 90 | 34 | 70 |
| Net income | 537 | 576 | 485 | 157 | 437 |
| Diluted EPS | $2.31 | $2.50 | $2.10 | $0.70 | $2.00 |
| Diluted shares (millions) | – | – | – | 225 | 219 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
5.14 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 30, 2026